{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:58Z","timestamp":1791216538230,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Diabetes Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is conflicting evidence regarding an association between gonadotropin releasing hormone analogue (GnRHa) therapy and polycystic ovary syndrome (PCOS). This study aimed to compare the prevalence of endocrine disorders, primarily PCOS, between women who had been treated with GnRHa for central precocious puberty (CPP) and those who were not treated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort study, including women diagnosed with central precocious puberty between 1989 and 2011 in a university affiliated tertiary medical center. Data collected included demographic data, medical background, clinical presentation at diagnosis and duration of treatment (zero for non-treated). Gynecologic and endocrine long-term outcomes were compared by treatment group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-one women were included in the study, 27\/51 had been treated with gonadotropin releasing hormone analogue (GnRHa). Overall prevalence of PCOS was 19.6%. No statistically significant difference in prevalence of PCOS was demonstrated between the treated and non-treated groups. Similarly, overall prevalence of either clinical or laboratory hyper-androgenism, was 29.4% and 33.3%, for the treatment and non-treatment groups respectively (<jats:italic>p\u2009<\/jats:italic>=\u2009non-significant).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GnRHa treatment for precocious puberty is not associated with increased risk of polycystic ovary syndrome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40842-021-00129-4","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T23:07:55Z","timestamp":1631660875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-4560","authenticated-orcid":false,"given":"Gilad","family":"Karavani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry H.","family":"Chill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natali","family":"Schachter-Safrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Lomnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvora","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"129_CR1","unstructured":"Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In: Williams Textbook of Endocrinology. 12th ed. Amsterdam: Elsevier Saunders; 2011. p. 1054\u2013201."},{"key":"129_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/er.2002-0019","volume":"24","author":"AS Parent","year":"2003","unstructured":"Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. 2003;24:668\u201393.","journal-title":"Endocr Rev"},{"key":"129_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1542\/peds.2005-0012","volume":"116","author":"G Teilmann","year":"2005","unstructured":"Teilmann G. Prevalence and incidence of precocious pubertal development in Denmark: An epidemiologic study based on national registries. Pediatrics. 2005;116:1323\u20138.","journal-title":"Pediatrics"},{"key":"129_CR4","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1210\/jc.2010-1025","volume":"95","author":"L Soriano-Guill\u00e9n","year":"2010","unstructured":"Soriano-Guill\u00e9n L, Corripio R, Labarta JI, Ca\u00f1ete R, Castro-Feij\u00f3o L, Espino R, et al. Central precocious puberty in children living in Spain: Incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab. 2010;95:4305\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"129_CR5","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1210\/jc.2013-1024","volume":"98","author":"JS Fuqua","year":"2013","unstructured":"Fuqua JS. Treatment and outcomes of precocious puberty: An update. J Clin Endocrinol Metab. 2013;98:2198\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"key":"129_CR6","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","volume":"358","author":"JC Carel","year":"2008","unstructured":"Carel JC, L\u00e9ger J. Clinical practice. Precocious puberty N Engl J Med. 2008;358:2366\u201377.","journal-title":"Precocious puberty N Engl J Med"},{"key":"129_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1542\/peds.2008-1783","volume":"123","author":"JC Carel","year":"2009","unstructured":"Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:752\u201362.","journal-title":"Pediatrics"},{"key":"129_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1210\/jcem-52-2-370","volume":"52","author":"W Crowly","year":"1981","unstructured":"Crowly W, Comite F, Vale W, Rivier J, Loriaux D, Cutler C. Therapeutic use of pituitary desensitization with long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981;52:370\u20132.","journal-title":"J Clin Endocrinol Metab"},{"key":"129_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","volume":"375","author":"CR McCartney","year":"2016","unstructured":"McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med. 2016;375:54\u201364.","journal-title":"N Engl J Med"},{"key":"129_CR10","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"129_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.fertnstert.2008.11.016","volume":"93","author":"R Franceschi","year":"2010","unstructured":"Franceschi R, Gaudino R, Marcolongo A, Gallo MC, Rossi L, Antoniazzi F, et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril. 2010;93:1185\u201391.","journal-title":"Fertil Steril"},{"key":"129_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1210\/jc.2009-0793","volume":"95","author":"MA Magiakou","year":"2010","unstructured":"Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010;95:109\u201317.","journal-title":"J Clin Endocrinol Metab"},{"key":"129_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-09-1102","volume":"163","author":"V Chiavaroli","year":"2010","unstructured":"Chiavaroli V, Liberati M, D\u2019Antonio F, Masuccio F, Capanna R, Verrotti A, et al. GnRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol. 2010;163:55\u201362.","journal-title":"Eur J Endocrinol"},{"key":"129_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.mce.2006.04.012","volume":"254","author":"S Heger","year":"2006","unstructured":"Heger S, M\u00fcller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol. 2006;254:217\u201320.","journal-title":"Mol Cell Endocrinol"},{"key":"129_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/cen.12319","volume":"80","author":"L Lazar","year":"2014","unstructured":"Lazar L, Meyerovitch J, De Vries L, Phillip M, Lebenthal Y. Treated and untreated women with idiopathic precocious puberty: Long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf). 2014;80:570\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"129_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41\u20137.","journal-title":"Hum Reprod"},{"key":"129_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajog.2010.03.008","volume":"203","author":"E Carmina","year":"2010","unstructured":"Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203:201\u20135.","journal-title":"Am J Obstet Gynecol"},{"key":"129_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2265.1995.tb01853.x","volume":"42","author":"NA Bridges","year":"1995","unstructured":"Bridges NA, Cooke A, Healy JR, Hindmarsh PC, Brook CGD. Ovaries in sexual precocity. Clin Endocrinol. 1995;42:135\u201340.","journal-title":"Clin Endocrinol"},{"key":"129_CR19","first-page":"285","volume":"68","author":"ME Escobar","year":"2007","unstructured":"Escobar ME, Ropelato MG, Ballerini MG, Gryngarten MG, Rudaz MC, Veldhuis JD, et al. Acceleration of luteinizing hormone pulse frequency in adolescent girls with a history of central precocious puberty with versus without hyperandrogenism. Horm Res. 2007;68:285\u20137.","journal-title":"Horm Res"},{"key":"129_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6\u201315.","journal-title":"Fertil Steril"},{"key":"129_CR21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/humupd\/dmz020","volume":"25","author":"JM Piovezan","year":"2019","unstructured":"Piovezan JM, Premaor MO, Comim FV. Negative impact of polycystic ovary syndrome on bone health: a systematic review and meta-analysis. Hum Reprod Update. 2019;25:634\u201346.","journal-title":"Hum Reprod Update"},{"key":"129_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fendo.2019.00222","volume":"10","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang Y, Wang Y, Li S, Wang L, Zheng J, et al. High thyroid stimulating hormone level is associated with hyperandrogenism in euthyroid polycystic ovary syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: a cross-sectional analysis. Front Endocrinol (Lausanne). 2019;10:222.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Clinical Diabetes and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-021-00129-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-021-00129-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-021-00129-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T23:20:28Z","timestamp":1631661628000},"score":1,"resource":{"primary":{"URL":"https:\/\/clindiabetesendo.biomedcentral.com\/articles\/10.1186\/s40842-021-00129-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1186\/s40842-021-00129-4","relation":{},"ISSN":["2055-8260"],"issn-type":[{"value":"2055-8260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"11 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Human Research Ethics Committees of the Hadassah University hospital (IRB number HMO -192\u201319).) and conforms to the provisions of the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}